Unknown

Dataset Information

0

A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma.


ABSTRACT: Over the past decade, therapies targeting the VEGF/VEGFR and mTOR pathways have served as the standard of care for the clinical management of renal cell carcinoma (RCC) patients. Albeit promising, these targeted drugs have attained only modest clinical benefits with limited prolonged progression-free survival. Therefore, alternative reasonable and applicable therapeutic approaches should be introduced to improve the clinical outcome of RCC patients. Methods: FDA approved kinase inhibitors were screened to evaluate their abilities to suppress the proliferation of RCC cells. Then, the downstream effector, therapeutic target and signaling pathway of the selected drug were identified by gene expression array, RNAi, kinase profile and rescue verification. Finally, the in vivo effectiveness of the drug was assessed in cell line-based xenograft models and patient-derived xenograft models. Results: In this study, we discovered that dasatinib is a potent agent that can impair RCC cell viability in vitro and decrease tumor growth in vivo. Mechanistically, we improved the understanding of the precise mechanistic role of YAP as a pivotal effector of dasatinib-induced anti-proliferation through Src-JNK-LIMD1-LATS signaling cascade in RCC cells. Meanwhile, our results indicated that the alteration of p-YAP is closely correlated to the growth inhibition caused by dasatinib in sensitive RCC models. Conclusion: Our findings provide evidence that dasatinib may serve as a powerful drug candidate to treat subgroups of RCC patients with hyper-activated Src-YAP signaling axis, and the alteration of p-YAP could serve as a functional response biomarker of dasatinib in RCC.

SUBMITTER: Sun J 

PROVIDER: S-EPMC6010995 | BioStudies | 2018-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC4792584 | BioStudies
2011-01-01 | S-EPMC3303496 | BioStudies
2018-01-01 | S-EPMC6170676 | BioStudies
1000-01-01 | S-EPMC5828210 | BioStudies
2014-01-01 | S-EPMC4160395 | BioStudies
2013-01-01 | S-EPMC3832668 | BioStudies
2014-01-01 | S-EPMC5161097 | BioStudies
2014-01-01 | S-EPMC4401074 | BioStudies
2016-01-01 | S-EPMC5239502 | BioStudies
2018-01-01 | S-EPMC5986022 | BioStudies